Novavax, Inc.
NASDAQ:NVAXBiotechnology
-$0.18 today
- Market cap
- $1.27B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
Volume 4.34M
Average 4.58M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Novavax, Inc.
NASDAQ:NVAX
Intrinsic Alpha fair value
Locked
Current Price
$7.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -15.2% (5yr)2 analysts |
| Revenue | N/A | N/A | -11.1% | -16.9% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | -15.2% (5yr)3 analysts |
| EBIT | N/A | N/A | N/A | -14.1% (5yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.1% over three years. Forward estimates point to EBIT at -14.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Moderna, Inc. NASDAQ:MRNA | $90.38B | $223.37 | Not rated | -7.9 | +791.46% |
BioNTech SE NASDAQ:BNTX | $21.22B | $85.60 | Not rated | -16.2 | -16.08% |
Vaxcyte, Inc. NASDAQ:PCVX | $10.03B | $63.37 | Not rated | -7.8 | +22.43% |
Valneva SE NASDAQ:VALN | $538.42M | $5.66 | Not rated | -2.9 | -37.10% |
Emergent BioSolutions Inc. NYSE:EBS | $297.69M | $5.79 | Undervalued | -47.9 | -43.28% |
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | $240.96M | $8.36 | Not rated | -2.7 | +28.81% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $98.80M | $1.43 | Not rated | -8.9 | -1.16% |
Continue the stock analysis
Jump to another research area for this company.